Psychedelic-assisted therapy: all studies (page 143)

Acute effects of MDMA, MDA, lysine-MDMA, and lysine-MDA in a randomized, double-blind, placebo-controlled, crossover trial in healthy participants.

Neuropsychopharmacology 2026 Isabelle Straumann, Patrick Vizeli, Isidora Avedisian et al. 5 citations

3,4-Methylenedioxymethamphetamine (MDMA) is used recreationally, as a research tool, and in MDMA-assisted therapy in patients with posttraumatic stress disorder. 3,4-Methylenedioxyamphetamine (MDA) is a psychoactive metabolite of MDMA. Acute effects of MDMA and MDA have never been directly compared in humans. Lysine-conjugated amphetamines slowly release active amphetamine once absorbed,...

DOI: 10.1038/s41386-025-02248-3 Full text

Inflammatory biomarker outcomes associated with MDMA-assisted therapy: an open-label exploratory study.

Frontiers in Neuroscience 2026 Jenna E Kachmarik, Jennifer M Loftis, Christopher S. Stauffer

Posttraumatic stress disorder (PTSD) is associated with elevated inflammation and risk for chronic illness, yet few studies have examined inflammatory biomarker outcomes of PTSD interventions. Rapid PTSD symptom reduction has been observed following 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy, which leverages MDMA as a prosocial adjunct to psychotherapy. No studies have evaluated...

DOI: 10.3389/fnins.2026.1716817 Full text MDMA Crp Il-6 Tnf-α +4

The therapeutic potential of ayahuasca in depression, generalized anxiety, and substance use disorders: modulation of the depressive burden in a longitudinal study.

Frontiers in Psychiatry 2026 Gláucio Silva Camargos, Geraldo Magela De Faria Júnior, Marcelo Lourenço et al.

This longitudinal observational study evaluated changes in depressive symptoms associated with ritualistic ayahuasca use in patients diagnosed with depressive disorders, as well as depressive burden in individuals with anxiety and substance use disorders. The research was conducted with 280 adults treated at clinics in the northwestern region of the state of São Paulo, under the jurisdiction of...

DOI: 10.3389/fpsyt.2026.1726909 Full text Ayahuasca Mental disorders Psychedelics Psychotherapy +1

Magnitude of response in treatment and control groups within psychedelic trials for psychiatric disorders: A meta-analysis

European Psychiatry 2026 Shakila Meshkat, Qiaowei Lin, Rachel Sousa-Ho et al.

Abstract Background Psychedelic-assisted psychotherapy has shown potential for psychiatric disorders. However, the magnitude of symptom change in control groups remains poorly understood. We aim to evaluate within-group effects in control groups and compare them to treatment groups in psychedelic trials. Methods A systematic search was conducted up to 1 July 2025. The study protocol was...

DOI: 10.1192/j.eurpsy.2026.10168 Full text Magnitude astronomy Control management Clinical trial Drug trial +1

New Antidepressant Development in the Treatment of Depression.

Advances in experimental medicine and biology 2026 Alessandro Spiti, Daniela Caldirola, Giampaolo Perna 1 citation

Major depressive disorder (MDD) continues to pose a major therapeutic challenge due to its clinical heterogeneity. This chapter looks at the development of antidepressant treatments, starting with early interventions such as electroconvulsive therapy (ECT), monoamine oxidase inhibitors (MAOIs) and tricyclic antidepressants (TCAs). Although these treatments targeted the monoaminergic system,...

DOI: 10.1007/978-981-95-6872-7_23 Full text Antidepressants Artificial intelligence Drug development Gabaergic system +3

Rural-Urban Disparities in Access to Interventional Psychiatry Treatments among VA Patients.

Rural mental health 2026 Brian Shiner, Vincent Dufort, Tayla Peltzman et al.

While tele-mental health has improved access to standard medication management and psychotherapy for rural Veterans, implementation of interventional psychiatry treatments will require in-person care, potentially leading to the exacerbation of rural-urban disparities in access to mental health care. We studied the availability of interventional psychiatry treatments, delivered clinically or in...

DOI: 10.1037/rmh0000333 Full text Major depressive disorder Posttraumatic stress disorder Therapeutic procedures Veterans

Healthcare Providers' Perspectives on Psychedelic-Assisted Therapies Across Clinical Contexts: "I Can Offer Medical Assistance in Dying, but I Can't Prescribe Psychedelics".

Global Advances in Integrative Medicine and Health 2026 Haley D M Schuman, Raèf Mina, Sofia Barkova et al.

Healthcare providers' (HCPs) perspectives on psychedelic-assisted therapy (PAT) are critical to clinical integration but remain underexplored in Canadian palliative and oncology contexts. This study examines HCP attitudes toward ketamine, psilocybin, and MDMA, and the systemic and ethical factors influencing implementation. An exploratory qualitative study using semi-structured interviews was...

DOI: 10.1177/27536130261459354 Full text MDMA Ketamine Psilocybin Cancer +2

Effects of Serotonergic Psychedelics on Synaptic Function and Neuroplasticity

OPUS FAU - Online publication system of Friedrich-Alexander-Universität Erlangen-Nürnberg 2026 Aneta Petrušková

INTRODUCTION: Sertonergic psychedelics LSD, psilocin and DMT, have been shown to hold a great potential for treatment of various neuropsychiatric conditions, such as major depressive disorder, addiction, and end-of-life anxiety. Effects of these substances on neuronal activity and plasticity have been demonstrated, however, better understanding of their mechanism of action is crucial for...

DOI: 10.25593/open-fau-2619 Serotonergic Synaptic plasticity Neuroplasticity Neurotransmission +11

A Randomized Controlled Trial of Psilocybin for the Treatment of Obsessive-Compulsive Disorder

Online Publication Service of Würzburg University (Würzburg University) 2026 Katja Ehrmann

Obsessive Compulsive Disorder (OCD) is a prevalent mental disorder, with a lifetime prevalence of 2-3%, characterized by intrusive thoughts (obsessions) and repetitive behaviors (compulsions). These thoughts and behaviors take up a significant amount of time, cause immense distress, and compromise the quality of life of those who suffer from OCD. In addition to psychological factors such as...

DOI: 10.25972/opus-43620 Psilocybin Default mode network Major depressive disorder Serotonergic +10

It’s all about the relationship: The caregiver experience of supporting a person with advanced cancer going through an LSD microdosing trial

Palliative & Supportive Care 2026 Fiona Cottam, Alesha Wells, Cerys Clayden et al.

Participation in trials investigating psychedelic-assisted MCP may offer hope for patients and their caregivers. Given the bidirectional relationship in wellbeing between cancer dyads, caregivers should be included alongside patients in such trials.

DOI: 10.1017/s1478951526101977 Full text Clinical trial Psychotherapist Terminal cancer Cancer treatment +7

Research